trial · primary record
Ocrelizumab
Multiple Sclerosis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 1300 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Incidence and severity of adverse events, with severity determined according to the NCI CTCAE v5.0 |
| Registry ID | NCT05269004 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:08.010Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05269004
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ocrelizumab · compound